MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/420/0.01/20.09.24

MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/420/0.01/20.09.24 Stock

DE000ME4N3B4

Market Closed - Börse Stuttgart 14:07:54 2024-07-05 EDT
0.63 ^EUR	+5.00%

Current month	-3.08%
1 month	-13.70%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart MORGAN STANLEY PLC/CALL/VERTEX PHARMACEUTICALS/420/0.01/20.09.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis	07-02	MT
Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy	07-02	DJ
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis	07-02	BU
Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, A Next-In-Class Triple Combination Treatment for Cystic Fibrosis	07-02	CI

More news

Quotes 5-day view

Date	Price	Change
24-07-05	0.63	+5.00%
24-07-04	0.6	+1.69%
24-07-03	0.59	-6.35%
24-07-02	0.63	+3.28%
24-07-01	0.61	-6.15%

Delayed Quote Börse Stuttgart

Last update July 05, 2024 at 02:07 pm

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	Morgan Stanley
WKN	ME4N3B
ISIN	DE000ME4N3B4
Date issued	2023-12-05
Strike	420 $
Maturity	2024-09-20 (76 Days)
Parity	100 : 1
Emission price	0.21 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	0.76 €
Lowest since issue	0.195 €
Delta	0.81x
Omega	5.699
Premium	2.8x
Gearing	7x
Moneyness	1.130
Difference Strike	-54.48 $
Difference Strike %	-12.97%
Spread	0.01 €
Spread %	1.59%
Theoretical value	0.6250
Implied Volatility	35.78 %
Total Loss Probability	23.33 %
Intrinsic value	0.5026
Present value	0.1224
Break even	487.74 €
Theta	-0.01x
Vega	0.01x
Rho	0.01x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

474.6 USD

Average target price

468.3 USD

Spread / Average Target

-1.33%

Consensus